Article ; Online: Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.
World journal of surgical oncology
2024 Volume 22, Issue 1, Page(s) 106
Abstract: Background: The survival outcomes in HER2-low versus HER2-zero breast cancer (BC) after neoadjuvant chemotherapy (NACT) remain unclear. The meta-analysis was conducted to summarize current evidence about the survival outcomes in HER2-low versus HER2- ... ...
Abstract | Background: The survival outcomes in HER2-low versus HER2-zero breast cancer (BC) after neoadjuvant chemotherapy (NACT) remain unclear. The meta-analysis was conducted to summarize current evidence about the survival outcomes in HER2-low versus HER2-zero BC. Methods: We conducted a systematic search in PubMed and EMBASE databases to identify relevant studies. Results: A total of 14 studies with 53,714 patients were included. Overall, 34,037 patients (63.37%) were HER2-low, and 19,677 patients (36.63%) were HER2-zero. Patients with HER2-low tumors had a significantly lower pathological complete response (pCR) rate than patients with HER2-zero tumors, regardless of the hormone receptor status. Compared with HER2-zero breast cancer, the overall survival (OS) and disease-free survival (DFS) of HER2-low BC were longer in the overall cohort (HR = 0.72; 95% CI = 0.61-0.85; P < 0.0001; HR = 0.83; 95% CI = 0.75-0.92; P = 0.0002); however, no differences were observed in terms of OS and DFS between HER2-low and HER2-zero BC in the HR-negative group. In the HR-positive group, HER2-low status had no significant impact on OS, while significantly associated with increased DFS (HR = 0.85; 95% CI = 0.76-0.96; P = 0.007). Conclusion: These results suggest that although HER2-low BC has a poor response to NACT, it is correlated with favorable OS and DFS after NACT in the overall cohort as well as longer DFS in the HR-positive group. |
---|---|
MeSH term(s) | Humans ; Female ; Breast Neoplasms/pathology ; Neoadjuvant Therapy ; Receptor, ErbB-2 ; Disease-Free Survival ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant |
Chemical Substances | Receptor, ErbB-2 (EC 2.7.10.1) |
Language | English |
Publishing date | 2024-04-20 |
Publishing country | England |
Document type | Meta-Analysis ; Journal Article |
ZDB-ID | 2118383-1 |
ISSN | 1477-7819 ; 1477-7819 |
ISSN (online) | 1477-7819 |
ISSN | 1477-7819 |
DOI | 10.1186/s12957-024-03382-w |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.